D M Roden

4.2k total citations · 2 hit papers
27 papers, 2.7k citations indexed

About

D M Roden is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, D M Roden has authored 27 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 12 papers in Molecular Biology and 9 papers in Pharmacology. Recurrent topics in D M Roden's work include Cardiac electrophysiology and arrhythmias (18 papers), Ion channel regulation and function (11 papers) and Pharmacogenetics and Drug Metabolism (6 papers). D M Roden is often cited by papers focused on Cardiac electrophysiology and arrhythmias (18 papers), Ion channel regulation and function (11 papers) and Pharmacogenetics and Drug Metabolism (6 papers). D M Roden collaborates with scholars based in United States, France and Sweden. D M Roden's co-authors include Teri E. Klein, Alan R. Shuldiner, Catherine M. Stein, Jean‐Sébastien Hulot, Stuart A. Scott, Katrin Sangkuhl, Jessica L. Mega, Julie A. Johnson, Marc S. Sabatine and Raymond L. Woosley and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and The American Journal of Cardiology.

In The Last Decade

D M Roden

26 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

2013 680 citations Stuart A. Scott, Katrin Sangkuhl et al. Clinical Pharmacology & Therapeutics profile →
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

2014 301 citations Laura B. Ramsey, Samuel G. Johnson et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D M Roden United States	20	1.1k	1.1k	615	457	417	27	2.7k
Patrick Kesteven United Kingdom	19	1.9k 1.7×	944 0.9×	319 0.5×	264 0.6×	295 0.7×	51	3.4k
Deepak Voora United States	27	1.5k 1.3×	802 0.8×	719 1.2×	367 0.8×	774 1.9×	102	3.6k
Andrea Jorgensen United Kingdom	32	1.4k 1.3×	509 0.5×	468 0.8×	488 1.1×	287 0.7×	107	3.7k
Julian Leathart United Kingdom	26	1.4k 1.2×	458 0.4×	612 1.0×	329 0.7×	229 0.5×	37	3.7k
Vera H.M. Deneer Netherlands	31	1.1k 1.0×	1.9k 1.8×	465 0.8×	562 1.2×	1.1k 2.6×	88	4.5k
Niclas Eriksson Sweden	23	2.1k 1.9×	1.2k 1.2×	486 0.8×	247 0.5×	260 0.6×	67	4.2k
Roland Valdes United States	29	571 0.5×	822 0.8×	840 1.4×	220 0.5×	192 0.5×	77	2.8k
Roberto Padrini Italy	27	646 0.6×	503 0.5×	402 0.7×	176 0.4×	343 0.8×	104	2.7k
Russell A. Wilke United States	34	1.4k 1.2×	470 0.4×	1.2k 2.0×	523 1.1×	854 2.0×	93	4.5k
Sara L. Van Driest United States	29	638 0.6×	1.5k 1.5×	864 1.4×	462 1.0×	261 0.6×	106	3.3k

Countries citing papers authored by D M Roden

Since Specialization

Citations

This map shows the geographic impact of D M Roden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D M Roden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D M Roden more than expected).

Fields of papers citing papers by D M Roden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D M Roden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D M Roden. The network helps show where D M Roden may publish in the future.

Co-authorship network of co-authors of D M Roden

This figure shows the co-authorship network connecting the top 25 collaborators of D M Roden. A scholar is included among the top collaborators of D M Roden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D M Roden. D M Roden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramsey, Laura B., Samuel G. Johnson, Kelly E. Caudle, et al.. (2014). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clinical Pharmacology & Therapeutics. 96(4). 423–428. 301 indexed citations breakdown →

Scott, Stuart A., Katrin Sangkuhl, Catherine M. Stein, et al.. (2013). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clinical Pharmacology & Therapeutics. 94(3). 317–323. 680 indexed citations breakdown →

Delaney, Jessica, Yang Shi, Jonathan S. Schildcrout, et al.. (2013). Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. EP Europace. 16(4). 485–490. 22 indexed citations

Ramirez, Andrea H., Christian M. Shaffer, Jessica Delaney, et al.. (2012). Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. The Pharmacogenomics Journal. 13(4). 325–329. 48 indexed citations

Roden, D M, Hua Xu, Joshua C. Denny, & Russell A. Wilke. (2012). Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges. Clinical Pharmacology & Therapeutics. 91(6). 1083–1086. 38 indexed citations

Schildcrout, Jonathan S., Joshua C. Denny, Erica Bowton, et al.. (2012). Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clinical Pharmacology & Therapeutics. 92(2). 235–242. 152 indexed citations

Pulley, Jill M., Joshua C. Denny, Gordon R. Bernard, et al.. (2012). Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clinical Pharmacology & Therapeutics. 92(1). 87–95. 298 indexed citations

Scott, Stuart A., Katrin Sangkuhl, Catherine M. Stein, et al.. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics. 90(2). 328–332. 362 indexed citations

Tatonetti, Nicholas P., Joshua C. Denny, G. Krishnan, et al.. (2011). Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical Pharmacology & Therapeutics. 90(1). 133–142. 156 indexed citations

10.

Roden, D M. (2005). Genetics of acquired long QT syndrome. Journal of Clinical Investigation. 115(8). 2025–2032. 164 indexed citations

11.

Roden, D M. (2000). Impact of Recent Molecular Studies on Evaluation of Ventricular Arrhythmias. Journal of Interventional Cardiac Electrophysiology. 4(S1). 7–16.

12.

Roden, D M & Michael M. Tamkun. (1994). Toward a molecular view of cardiac arrhythmogenesis. Trends in Cardiovascular Medicine. 4(6). 278–285. 5 indexed citations

13.

Turgeon, Jacques, et al.. (1991). Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clinical Pharmacology & Therapeutics. 49(5). 488–496. 6 indexed citations

14.

Reilly, Charles S., Richard P. Koshakji, D M Roden, et al.. (1990). Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade.. Journal of Clinical Investigation. 85(3). 836–842. 27 indexed citations

15.

Turgeon, Jacques, et al.. (1990). Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.. Journal of Pharmacology and Experimental Therapeutics. 255(2). 642–649. 15 indexed citations

16.

Kroemer, Heyo K., Jacques Turgeon, Robert A. Parker, & D M Roden. (1989). Flecainide enantiomers: Disposition in human subjects and electrophysiologic actions in vitro. Clinical Pharmacology & Therapeutics. 46(5). 584–590. 19 indexed citations

17.

Thompson, Katherine A., John Murray, Ian A. Blair, Raymond L. Woosley, & D M Roden. (1988). Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clinical Pharmacology & Therapeutics. 43(6). 636–642. 36 indexed citations

18.

Siddoway, Lyle A., et al.. (1988). The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias. Clinical Pharmacology & Therapeutics. 43(5). 499–508. 6 indexed citations

19.

Roden, D M, et al.. (1984). Influence of genetic polymorphism on the metabolism and disposition of encainide in man.. Journal of Pharmacology and Experimental Therapeutics. 228(3). 605–611. 78 indexed citations

20.

Roden, D M, et al.. (1982). Antiarrhythmic activity of the O-demethyl metabolite of encainide.. Journal of Pharmacology and Experimental Therapeutics. 221(3). 552–557. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact